Bill Full Text
Home
-
Bills
-
Bill
-
Authors
-
Dates
-
Locations
-
Analyses
-
Organizations
<?xml version="1.0" ?>
<ns0:MeasureDoc xmlns:html="http://www.w3.org/1999/xhtml" xmlns:ns0="http://lc.ca.gov/legalservices/schemas/caml.1#" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" version="1.0" xsi:schemaLocation="http://lc.ca.gov/legalservices/schemas/caml.1# xca.1.xsd">
<ns0:Description>
<ns0:Id>20250AB__244299INT</ns0:Id>
<ns0:VersionNum>99</ns0:VersionNum>
<ns0:History>
<ns0:Action>
<ns0:ActionText>INTRODUCED</ns0:ActionText>
<ns0:ActionDate>2026-02-20</ns0:ActionDate>
</ns0:Action>
</ns0:History>
<ns0:LegislativeInfo>
<ns0:SessionYear>2025</ns0:SessionYear>
<ns0:SessionNum>0</ns0:SessionNum>
<ns0:MeasureType>AB</ns0:MeasureType>
<ns0:MeasureNum>2442</ns0:MeasureNum>
<ns0:MeasureState>INT</ns0:MeasureState>
</ns0:LegislativeInfo>
<ns0:AuthorText authorType="LEAD_AUTHOR">Introduced by Assembly Member Patterson</ns0:AuthorText>
<ns0:Authors>
<ns0:Legislator>
<ns0:Contribution>LEAD_AUTHOR</ns0:Contribution>
<ns0:House>ASSEMBLY</ns0:House>
<ns0:Name>Patterson</ns0:Name>
</ns0:Legislator>
</ns0:Authors>
<ns0:Title> An act relating to public health. </ns0:Title>
<ns0:RelatingClause>public health</ns0:RelatingClause>
<ns0:GeneralSubject>
<ns0:Subject>Peptides.</ns0:Subject>
</ns0:GeneralSubject>
<ns0:DigestText>
<html:p>Existing law, the Sherman Food, Drug, and Cosmetic Law, under the administration and enforcement of the State Department of Public Health, provides for the regulation of various subjects relating to the manufacturing, processing, labeling, advertising, and sale of food, drugs, and cosmetics.</html:p>
<html:p>This bill would state the intent of the Legislature to enact legislation to support state-authorized research programs, investigational therapeutic access under medical supervision, institution-level safety oversight, and high-quality manufacturing and testing standards for peptides. The bill would further state the intent of the Legislature to enact legislation to establish a state-authorized research and investigational therapeutic framework for peptides that complements existing federal regulatory structures while expanding opportunities for scientific
research and medically supervised investigational therapeutic access.</html:p>
</ns0:DigestText>
<ns0:DigestKey>
<ns0:VoteRequired>MAJORITY</ns0:VoteRequired>
<ns0:Appropriation>NO</ns0:Appropriation>
<ns0:FiscalCommittee>NO</ns0:FiscalCommittee>
<ns0:LocalProgram>NO</ns0:LocalProgram>
</ns0:DigestKey>
<ns0:MeasureIndicators>
<ns0:ImmediateEffect>NO</ns0:ImmediateEffect>
<ns0:ImmediateEffectFlags>
<ns0:Urgency>NO</ns0:Urgency>
<ns0:TaxLevy>NO</ns0:TaxLevy>
<ns0:Election>NO</ns0:Election>
<ns0:UsualCurrentExpenses>NO</ns0:UsualCurrentExpenses>
<ns0:BudgetBill>NO</ns0:BudgetBill>
<ns0:Prop25TrailerBill>NO</ns0:Prop25TrailerBill>
</ns0:ImmediateEffectFlags>
</ns0:MeasureIndicators>
</ns0:Description>
<ns0:Bill id="bill">
<ns0:Preamble>The people of the State of California do enact as follows:</ns0:Preamble>
<ns0:BillSection id="id_03D66672-BFA4-4DA6-9C80-1002BEDB3063">
<ns0:Num>SECTION 1.</ns0:Num>
<ns0:Content>
<html:p>The Legislature finds and declares all of the following:</html:p>
<html:p>
(a)
<html:span class="EnSpace"/>
California is a global leader in biotechnology, biomedical research, and pharmaceutical innovation.
</html:p>
<html:p>
(b)
<html:span class="EnSpace"/>
Many promising peptide-based therapeutic compounds demonstrate potential benefit in early research settings but do not progress through traditional drug development pathways due to economic, patent, or market limitations.
</html:p>
<html:p>
(c)
<html:span class="EnSpace"/>
Expanded research and investigational therapeutic access programs may accelerate scientific discovery while maintaining appropriate patient safety protections.
</html:p>
<html:p>
(d)
<html:span class="EnSpace"/>
Advancing peptide research supports innovation in areas including, but not limited to, rare disease research, health aging and longevity science, veteran therapeutic innovation, obesity and metabolic disease treatment, and neurodegenerative disease research.
</html:p>
<html:p>
(e)
<html:span class="EnSpace"/>
The Legislature recognizes that existing federal drug approval pathways are primarily structured to support large-scale commercial drug development models and may not fully accommodate emerging peptide research, early-stage therapeutic innovation, or compounds lacking traditional commercial sponsorship. The Legislature further recognizes that certain peptide compounds may demonstrate scientific or therapeutic potential but may not advance through traditional development pathways due to cost, market size, or lack of patent exclusivity.
</html:p>
<html:p>
(f)
<html:span class="EnSpace"/>
It is the intent of the Legislature to enact legislation to support
state-authorized research programs, investigational therapeutic access under medical supervision, institution-level safety oversight, and high-quality manufacturing and testing standards for peptides.
</html:p>
<html:p>
(g)
<html:span class="EnSpace"/>
It is the intent of the Legislature to enact legislation to establish a state-authorized research and investigational therapeutic framework for peptides that complements existing federal regulatory structures while expanding opportunities for scientific research and medically supervised investigational therapeutic access.
</html:p>
</ns0:Content>
</ns0:BillSection>
</ns0:Bill>
</ns0:MeasureDoc>